Sharing data from clinical trials: the rationale for a controlled access approach. by Sydes, MR et al.
METHODOLOGY Open Access
Sharing data from clinical trials: the rationale for a
controlled access approach
Matthew R Sydes
*, Anthony L Johnson, Sarah K Meredith, Mary Rauchenberger, Annabelle South and Mahesh KB Parmar
Abstract
Background: The move towards increased transparency around clinical trials is welcome. Much focus has been on
under-reporting of trials and access to individual patient data to allow independent verification of findings. There are
many other good reasons for data sharing from clinical trials. We describe some key issues in data sharing, including
the challenges of open access to data. These include issues in consent and disclosure; risks in identification, including
self-identification; risks in distorting data to prevent self-identification; and risks in analysis. These risks have led us to
develop a controlled access policy, which safeguards the rights of patients entered in our trials, guards the intellectual
property rights of the original researchers who designed the trial and collected the data, provides a barrier against
unnecessary duplication, and ensures that researchers have the necessary resources and skills to analyse the data.
Methods: We briefly discuss the practicalities of our current approach to data sharing, including ensuring that data are
discoverable and how to deal with old studies. We describe data sharing activities at the MRC Clinical Trials Unit.
Results: One hundred and three data sharing activities were logged from 2012 to 2014 from external and internal
applicants. The motivations are varied, but none have been for replication of the primary results.
Conclusions: For any request to share data, we note the important role of independent reviewers as well as
reviewers who know the study well, and present some of the key questions that all reviewers should ask when
deciding whether a request is reasonable. We consider the responsibilities of all parties. We highlight the potential
for opportunity costs. Clinical trial data should be shared for reasonable requests but there are many practical
issues that must be explicitly considered.
Background
The move towards increased transparency around clinical
trials is welcome. Under-reporting hampers understanding
of the benefits and harms of treatments. Reporting of trials
and access to data are current issues, with much discus-
sion around access to individual patient data (IPD) for in-
dependent verification of findings. However, there are
other reasons for data release that stem from the ethical
obligation to ensure optimal use of data collected in trials
including:
 Independent verification of original results
 Placing the results of studies in a broader context:
for example, individual patient data meta-analysis
 Secondary use of datasets; for example, using a trial
as a convenience sample of high quality,
prospectively-collected data to address issues
different from the original research objectives
 Collaborating directly with other researchers where
data need to be transferred to an alternative location
for planned analyses: for example, pre-planned
biological sub-studies or retrospective connection
of individual outcomes to diagnostic samples
 Supporting evidence for planning new trials: for
example, estimating event rate counts
 Developing new or improved statistical methodologies
The Medical Research Council Clinical Trials Unit at
UCL (the ‘Unit’) has many years’ experience in designing,
conducting, analysing and reporting clinical trials and
other studies, including IPD meta-analyses and cohorts.
Consequently, the Unit holds hundreds of datasets,
extending back several decades, and is well versed in the
issues associated with data sharing, both from the giver’s
and recipient’s perspective.
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guidance statements, or organised workshops on this
issue, or submitted commentaries (Additional file 1:
Table S1) [1-21]. The most comprehensive statement is
the Discussion Framework for Clinical Trial Data Shar-
ing: Guiding Principles, Elements, and Activities from
the Institute of Medicine’s( I O M )Sharing Clinical Trial
Data: Maximizing Benefits, Minimizing Risk [19] in
the USA which followed a discussion process [8]. The
final version of the European Medicines Agency (EMA)
policy on data release, which will have regulatory impact
throughout Europe, has recently been released [22]. The
consultative engagement by the EMA with parties
representing all relevant disciplines is noteworthy. The
EMA has recognised that there are issues in sharing
IPD and the published report focuses on access to Clin-
ical Study Reports.
Our Unit fully supports the use of clinical study data
for additional, ethical research with justified scientific
objectives. However, we believe there are a number of
problems with the completely open access approach ad-
vocated by some groups and journals. We describe these
and other key issues we face in sharing data.
Issues in consent and disclosure
We are mindful that people who consent to enter clin-
ical trials are voluntarily subjecting themselves to ex-
perimentation and donating their personal clinical data
to a team of medical researchers. They volunteer on the
understanding that these researchers will conduct the
trial responsibly, without unnecessary or illegitimate
identification of the individuals involved. They may also
allow their data to be passed to regulators for use in
decisions about drug licensing. The protection of their
data is described to the patient in the consent proce-
dures when entering a trial. None of our clinical trials
have asked for consent to disclose IPD data on the
Internet. There are exceptions where explicit consent
cannot be given directly by the patient and instead
consent has to be provided by a third party: for ex-
ample, trials in children or in adults who lack capacity
through, for example, dementia or who are unconscious.
We are unaware of published policy statements that
address the issues of data disclosure in trials requiring
assent.
Risks in identification and self-identification
Many trial participants, especially those with chronic or
rare diseases, are likely to be able to identify themselves in
open access datasets from combinations of variables such
as: age; sex; location; dates of consent, randomisation and
follow-up appointments; and health parameters. Ideally,
study doctors would discuss with participants all clinical
information collected, but in the routine setting of busy
hospital clinics, there is limited time and a host of
blood test results that measure specific potential toxic-
ities may be reduced to a simple ‘your blood tests were
fine’ response. Self-identification in open access data-
sets and discovery of these test results may lead to
concern and anxiety without the study doctor available
to provide context and interpretation. Furthermore,
adverse events may be technically classified as ‘serious’
according to standard regulatory definitions, but not be
clinically ‘severe’ or regarded as ‘serious’ from the par-
ticipant’s perspective. We regard disclosure of IPD
outside the doctor-patient environment as potentially
unethical and distressing, and possibly dangerous. Fam-
ily and friends of a study participant or other inquisitive
parties might also be able to identify them from open
access data and learn sensitive, possibly stigmatising,
information that the participant has chosen not to
disclose.
Risks in anonymisation and data distortion
Some people advocate for complete anonymisation or
de-identification of clinical trials data. This reflects dis-
cussions in the context of ‘big data’. However, it is clear
that current anonymisation methods are imperfect and
that re-identification is possible [23].
Some advocate that data for open access can be dis-
torted to prevent identification but distortion of key
variables can disable researchers’ ability to replicate
published results, thwarting a key aim of many advo-
cates of broader data access. Distorting data does not
completely de-couple it from patients in the trial. Par-
ticipants could still use closest-match algorithms or
even visually scan the dataset to identify the closest
match to their own records. Some people might be dis-
tressed if fundamental characteristics like age and sex
have been distorted and could even demand correction
under data protection regulations. Distortion of con-
tinuous parameters may carry reported values across
clinical thresholds which would normally trigger add-
itional treatment: for example, blood pressure and anti-
hypertensives or cholesterol and statins. This might cause
concern to participants as to their management, or leave
researchers reflecting inappropriately on the quality of the
trial and its data. Therefore, distortion is not appropriate.
Neither do we support attempts to distort data to
anonymise or de-identify it, specifically to de-couple
it from the original patients. We consider that such
manipulation has not been addressed adequately in any
of the published policy documents, and currently we do
not regard it as feasible.
Risks in analysis and dissemination
Unrestricted access to data could result in data dredging
and a plethora of analyses that were never intended
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strategy. First, data dredging is likely to provide some
false positive findings and lead to over-interpretation.
Second, we are also concerned that unrestricted access
to data could result in re-analysis of trials after their
initial publication resulting in public disagreements
about interpretation. Together these may lead partici-
p a n t st ow o r r ya b o u tw h a tt h e yh a v ee x p o s e dt h e m -
selves to, and raise public concerns about clinical trials
i ng e n e r a l .S p o n s o r sh a v ead u t yo fc a r et op r o v i d ea n
adequate explanation to patients when there is contro-
versy over the results.
Trialists set a high bar on who is qualified to analyse
clinical trial data and pre-specification of key analyses is
a pre-requisite of clinical trials. This standard must be
maintained for subsequent uses of the data. Only a con-
trolled access approach can achieve this.
Opportunity costs
The time and effort required to prepare datasets for re-
lease should not be under-estimated. Receiving and
processing applications, developing agreements and
contracts, producing and transferring data, and respond-
ing to subsequent requests for clarification involves a
broad range of functions across the Unit. In this resource-
limited environment, there will inevitably be opportunity
costs: data sharing activities may conflict with other de-
mands on staff time, such as other ongoing research. An
open access approach demands that the burdensome
process of making all data ready for sharing is under-
taken for all trials, regardless of the likelihood of future
use of the data and whether support to prepare datasets
is available. Core support is necessary from funding
bodies to allow for the preparation of datasets. Even the
activities in processing and considering applications re-
quires large amounts of time. In the absence of core
support, trials units may require applicants to provide
funding to cover the necessary staff time. This is im-
portant, especially for older studies where the original
grant has ended.
Collaboration
A controlled access approach may bring opportunities for
collaboration that an open access approach cannot. Trials
unit representatives and other key trial team members
should usually expect to be active collaborators in relevant
projects built upon the trials work that they have under-
taken, and not just passive providers of data.
Methods
We reviewed data sharing activities from the trials and IPD
meta-analyses at the MRC Clinical Trials Unit (CTU). For
this purpose, we have defined a ‘data sharing activity’ as a
r e q u e s tf o rI P Do rs u m m a r yd a t af o ro n et r i a lo rm e t a -
analysis beyond the original plans for that study, regardless
of the outcome of the application for access to data. We
have systematically logged activities since January 2012
and report to December 2014. Where possible, the mo-
tivation has been recorded. We use descriptive methods
to summarize these activities.
Results
We have logged 103 formal data sharing activities across
54 trials and IPD MAs in 2012, 2013 and 2014. A fur-
ther 74 formal activities are logged on the system before
this time, as are 4 informal activities for which formal
applications are expected soon.
The release of data was approved in 80 of these 103
activities; 17 reviews are pending or ongoing, and 2 were
abandoned by the applicants. Only four activities in this
period were rejected. One request for data from three
trials was rejected for scientific reasons and one was
rejected because the trial data were not yet available.
Seventy-one data sharing activities were led by external
parties. Only four requests were for processed summary
data, the majority being for IPD. Four activities in 2014
related to trials that recruited in the 1970s and 1980s,
including one for which no data had ever previously
been requested.
The most common motivation was methodology (41/
103 activities), mostly internal to the unit. Other motiva-
tions were connecting trial data to biology samples (22),
use in meta-analysis (13), other clinical projects (11) and
other reasons (1). One activity was for re-analysis using
alternative methods, relating to a tuberculosis (TB) trial
that recruited in the 1970s. The motivation was not
initially recorded on our data release forms and is un-
known for 14 activities. None of the activities logged
were to replicate the original analyses.
Discussion
MRC CTU at UCL approach
The approach we have developed to sharing data is in re-
sponse to the considerations outlined above, in conjunc-
tion with our extensive experience of managing and
sharing data from clinical trials and other studies across
many specialties of medicine over a long time. We have
chosen a controlled access approach whereby researchers
make formal applications for data sharing. Key people, in-
cluding the trial team and independent reviewers, review
these. Our approach is based on a set of guiding principles
that we believe should not be compromised:
 There must be a strong scientific argument or other
legitimate rationale for the data to be used for the
requested purpose
 No data can be released if this would compromise
an ongoing trial
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developing a trial should have a period of exclusivity
in which to pursue their aims, before key trial data
are made available to other researchers
 The resources required to process requests should
not be under-estimated, particularly those needed to
prepare data for release. Adequate resources must
be available and the scientific aims of the study must
justify the use of such resources
 All data exchange must comply with Information
Governance and Data Protection Policies
in all countries relevant to the disclosure
 All Unit trials must be ‘discoverable’; they are
formally entered on recognised clinical trials
registers, such as clinicaltrials.gov and
controlled-trials.com, and listed on the Unit’s
website [24]. Eligibility criteria for each study and
a list of information collected in it are available
(sometimes only on request). This combination of
information is intended to prevent researchers
from submitting requests that cannot be met,
such as data that were never collected or
populations that were not studied. Timelines
to indicate when data might be made available
m a ya l s ob ep o s t e d ,s u b j e c tt oa n yn e c e s s a r y
updating
Processing data sharing applications
There are many necessary steps prior to any release of
data. The Unit’s assessment process is staged and iterative,
includes independent review, and may be terminated at
any point. Our process, which applies equally to external
and internal applicants, is detailed in the Additional file 1.
Applicants are asked for information that allows reviewers
to consider the: objectives; study design; qualifications
and suitability; data required; samples required; ethical
approval and consent requirements; planned outputs;
authorship and publication policy; implications for the
Unit; funding and resources needed and support available;
and, timelines. A detailed protocol and statistical analysis
plan are required along with other relevant documents:
for example, grant applications, ethics approval.
Since applications for data sharing may be received long
after a trial has closed and reported its primary results, the
key study oversight committees should remain available
for as long as feasible to consider them. Alternative proce-
dures to provide late review should be decided before
these key committees are disbanded. An approach the
Unit has used is to ask the views of key ex-Trial Manage-
ment Group (TMG) members, with independent review
provided by another Trial Steering Committee (TSC)
active in the same area of medicine. Tissue samples are a
finite resource and careful discussion is required around
access. Requests to access data from trials that have
closed require specific approval from the Research Eth-
ics Committee, and will consider issues in consent.
The need for formal agreements
Successful external applications require a ‘data sharing
agreement’, usually agreed at an institutional level. These
agreements formalise key matters, including data trans-
fer and storage, updates, publication, and the boundaries
for further use, including, for example, that data can
only be used for the specified purpose. Applicants must
agree not to use the data to try to identify individual pa-
tients, unless this is a pre-specified purpose for record
linkage: for example, to retrieve follow-up information
on lost patients for an IPD meta-analysis. Our datasets
may already include linked data from other sources: for
example, National Health Service (NHS) Information
Centre data on deaths. These are considered part of the
dataset and can be included in data released by the Unit,
subject to agreement and approval by the original source.
Onward sharing, which is increasingly common around
linked genetic samples, is restricted unless clearly specified
and agreed (Additional file 1: Table S3).
Preparation and transfer
To facilitate future data sharing, wherever appropriate
and possible, we use standardised terms and definitions,
standard collection and scoring tools and internationally
agreed outcome measures [25]. The Unit takes particular
care in releasing identifiable or sensitive data. Indeed,
our data sets do not typically contain direct identifiers,
but, if collected to facilitate data linkage, they are usually
held separately from the main dataset and would not usu-
ally be included in released datasets. Indirect identifiers
are usually removed prior to disclosure; age or year-of-
birth may be used instead of date-of-birth, for example.
Consideration is given to replacing ID numbers to break
the link to our original dataset but de-identification
through data distortion is not used.
Data may only be transferred by appropriately secure
methods, after discussion with relevant experts in the
Unit’s Data Management Systems and Information Services
Group. Recipients must agree to store the data securely,
according to Information Governance and Data Protec-
tion regulations.
After data release
Recipients are asked to acknowledge receipt of data and
to check immediately for problems. They must have
appropriately qualified analysts, and may be asked to
reproduce an already completed analysis to ensure the
dataset is fully understood. A clear governance process
is established to handle discrepancies between the original
and replicated findings. Routes to discuss these findings
and possible arbitration are established in the agreement if
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method of analysis that might lead to a different interpret-
ation of a study’sf i n d i n g s .
Recipients are expected to publish their research promptly,
according to their pre-specified plans. The Unit requires
regular updates on projects involving released data for review
by the study’s oversight committees. All parties are obliged
to ensure that the data are used promptly.
Other notable examples
GlaxoSmithKline (GSK) and partners have recently imple-
mented the Clinical Study Data Request (CSDR) system
[26]. This is also a controlled access model, although quite
distinct from our own. With CDSR, requests for access
to data are considered by, but not scientifically reviewed
by, an independent panel [27]. Data are uploaded for trials
at a time of each company’s choosing. After 1 year there
were 1,200 studies available and 58 requests had been
submitted [27]. The motives for the requests were not
reported, but these analyses would be performed without
the engagement of the original research teams and without
collaborative opportunity.
Conclusions
While strongly supporting the imperative to share data,
we believe that there are a number of issues that require
further consideration before open access to clinical trial
data is possible and have therefore chosen to adopt a
controlled access approach, where a reasonable request
has a specific and justifiable scientific merit. This helps
to safeguard the rights of patients who enter our trials,
protect the intellectual property rights of the researchers
who designed the trial and collected the data, and pro-
vide a barrier against unnecessary duplication. It also en-
sures that researchers have the necessary resources and
capability to manipulate and analyse the data in accord-
ance with their stated aims as specified in a statistical
analysis plan. Funders and journals should withhold
mandates for completely open access until these consid-
erations have been adequately addressed. The current
need to control access should never stand in the way of
reasonable requests for data sharing.
Additional file
Additional file 1: The additional file summarises the approach used
for data sharing activities at MRC CTU, including some of the
questions that reviews should consider. It also considers some of the
issues that researchers who have received data face when receiving requests
to share the data further. The file also includes a list of organisations that
have published interim or final policy or guidance statements or organized
workshops.
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